Revance Therapeutics Inc (NASDAQ: RVNC) delivered a solid Q2 of RHA filler sales of $25.5 million, up 22%Q/Q and 50%Y/Y. OPUL/HintMD revenues reached $1.2 million (+43%Q/Q). Needham says that the main ...
In a wrinkle-reduction market run by AbbVie’s Botox™ (active ingredient onabotulinumtoxinA), Revance was just approved to distribute DAXXIFY™ (DAXI), a drug that reduces the appearance of facial ...
Robert Sietsema is the former Eater NY senior critic with more than 35 years of experience covering dining in New York City. Oohs and aahs went up as the waiter wearing a red neckerchief bore a bamboo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results